FTC and States Seek Contempt Charges Against Martin Shkreli Over Industry Ban
The Federal Trade Commission and seven states have petitioned a federal court to hold Martin Shkreli in contempt for allegedly violating a lifetime ban from the pharmaceutical industry. The filing claims Shkreli has continued to exert influence over companies despite the court-ordered prohibition.
The Federal Trade Commission (FTC), alongside a coalition of seven states, has formally requested that a federal court hold Martin Shkreli in contempt of court. The motion, filed in the U.S. District Court for the Southern District of New York, alleges that Shkreli has "flagrantly and repeatedly" violated a lifetime ban imposed on him, which prohibits his involvement in the pharmaceutical industry.
This legal action follows a previous judgment that barred Shkreli from the industry after he was found liable for anticompetitive practices related to the drug Daraprim. The FTC contends that Shkreli has continued to operate within the sector, defying the court's authority. The agency is now seeking judicial intervention to enforce the original ban and penalize the alleged non-compliance. As of the current filing, Shkreli has not publicly detailed his defense against these specific contempt allegations, and the court has yet to issue a ruling on the request for sanctions.
📡 Media Analysis
How each outlet framed the story — angles, word choices, and what they chose to push or ignore.
Reported the FTC's legal filing as a straightforward update on a high-profile regulatory enforcement action.
"flagrantly and repeatedly"
🔍 What Nobody's Reporting
- ·Lack of response or statement from Martin Shkreli or his legal counsel regarding the allegations.
- ·Specific examples or evidence of the 'violations' Shkreli is accused of committing.
📰 Sources
0 A-rated source(s) among 1 total. Lowest trust: The Hill (B)